Perianesthesia Care of the Oncologic Patient Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Study

被引:1
|
作者
Li, Dan [1 ]
Huang, Shi [2 ]
Zhang, Fei [3 ]
Ball, Ryan D. [4 ]
Huang, Heng [5 ]
机构
[1] Univ Pittsburgh, Dept Hlth & Community Syst, Sch Nursing, 426 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA
[2] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA
[3] Univ Pittsburgh, Sch Nursing, Dept Nurse Anesthesia, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Sch Med, UPMC Dept Anesthesiol & Perioperat Med, Pittsburgh, PA 15261 USA
[5] Univ Pittsburgh, Dept Elect & Comp Engn, Pittsburgh, PA 15261 USA
关键词
perianesthesia care; hyperthermic intraperitoneal chemotherapy; postoperative complications; PERITONEAL CARCINOMATOSIS; PERIOPERATIVE MANAGEMENT; HYDROXYETHYL STARCH; COLORECTAL-CANCER; ANESTHETIC MANAGEMENT; SURVIVAL OUTCOMES; OVARIAN-CANCER; CLAVIEN-DINDO; FLUID THERAPY; COMPLICATIONS;
D O I
10.1016/j.jopan.2020.10.016
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Purpose: This study was to understand the perianesthesia care for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). Method: This is a retrospective study. Design: The perioperative electronic medical records of 189 CRS + HIPEC surgical cases at a hospital of Western Pennsylvania from 2012 to 2018 were analyzed to study the characteristics of perianesthesia care for CRS + HIPEC surgery. Findings: The patients' median age was 57 (range 21-83) years, and 60% were men. The mean anesthesia time was 10.47 +/- 2.54 hours. Most tumors were appendix or colorectal in origin, and the mean peritoneal cancer index score was 16.19 +/- 8.76. The mean estimated blood loss was 623 +/- 582 mL. The mean total intravenous crystalloid administered was 8,377 +/- 4,100 mL. Fifty-two patients received packed red blood cells during surgery. Postoperatively, 100% of the patients were transferred to the intensive care unit. A majority (52%) of patients were extubated in the operating room. Median lengths of hospital and intensive care unit stays were 13 and 2 days, respectively. A majority (73%) of patients had 1 or more postoperative complications and 29% of patients experienced major postoperative complications (Clavien-Dindo grade III or higher) during the hospital stay. Prolonged hospitalization was owing to gastrointestinal dysfunctions and respiratory failure related to atelectasis and pleural effusion. Conclusions: CRS + HIPEC is a major surgery with numerous challenges to the perianesthesia care team regarding hemodynamic adjustment, pain control, and postoperative complications, which demand training and future studies from the perianesthesia care team. (c) 2020 American Society of PeriAnesthesia Nurses. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:543 / 552
页数:10
相关论文
共 50 条
  • [41] Outcome of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Patients with Diaphragmatic Involvement
    Franssen, Bernardo
    Tabrizian, Parissa
    Weinberg, Alan
    Romanoff, Anya
    Tuvin, Daniel
    Labow, Daniel
    Sarpel, Umut
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (05) : 1639 - 1644
  • [42] Anastomotic leakage following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A clinical cohort study
    Herzberg, Jonas
    Acs, Miklos
    Guraya, Salman Yousuf
    Schlitt, Hans Juergen
    Honarpisheh, Human
    Strate, Tim
    Piso, Pompiliu
    SURGICAL ONCOLOGY-OXFORD, 2024, 54
  • [43] Urgent re-laparotomies in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Manoglu, Berke
    Sokmen, Selman
    Bisgin, Tayfun
    Yildirim, Yasemin
    Cevlik, Ali Durubey
    Erdost, Hale Aksu
    Obuz, Funda
    ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY, 2022, 28 (10): : 1389 - 1396
  • [44] Imaging of pre- and post-cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pediatric intraperitoneal malignancy
    Hull, Nathan C.
    Granberg, Candace F.
    Gargollo, Patricio C.
    Thacker, Paul G.
    PEDIATRIC RADIOLOGY, 2022, 52 (12) : 2254 - 2266
  • [45] Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer
    Philipp Horvath
    Ingmar Königsrainer
    memo - Magazine of European Medical Oncology, 2020, 13 : 426 - 429
  • [46] Prophylactic Cholecystectomy is Safe in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
    Hanna, David N.
    Khajoueinejad, Nazanin
    Ghani, Muhammad O.
    Hermina, Andrew
    Mina, Alexander
    Bailey, Christina E.
    Cohen, Noah
    Labow, Daniel
    Golas, Benjamin
    Sarpel, Umut
    Idrees, Kamran
    Magge, Deepa
    AMERICAN SURGEON, 2024, 90 (06) : 1577 - 1581
  • [47] Melphalan: A Promising Agent in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Sardi, Armando
    Jimenez, William
    Nieroda, Carol
    Sittig, Michelle
    Shankar, Suven
    Gushchin, Vadim
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (03) : 908 - 914
  • [48] Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center
    Berger, Yaniv
    Aycart, Samantha
    Mandeli, John P.
    Heskel, Marina
    Sarpel, Umut
    Labow, Daniel M.
    SURGICAL ONCOLOGY-OXFORD, 2015, 24 (03): : 264 - 269
  • [49] Melphalan: A Promising Agent in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Armando Sardi
    William Jimenez
    Carol Nieroda
    Michelle Sittig
    Suven Shankar
    Vadim Gushchin
    Annals of Surgical Oncology, 2014, 21 : 908 - 914
  • [50] A review of 111 anaesthetic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Thong, Sze Ying
    Chia, Claramae Shulyn
    Ng, Oriana
    Tan, Grace
    Ong, Ee Teng
    Soo, Khee Chee
    Teo, Melissa
    SINGAPORE MEDICAL JOURNAL, 2017, 58 (08) : 488 - 496